Source:http://linkedlifedata.com/resource/pubmed/id/12002703
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2002-5-10
|
pubmed:abstractText |
The purpose of this study was to analyse the occurrence of non-visualisation during preoperative lymphoscintigraphy for sentinel node identification in breast cancer. Preoperative lymphoscintigraphy was performed in 495 clinically node-negative breast cancer patients (501 sentinel node procedures) after injection of technetium-99m nanocolloid. Anterior and prone lateral (hanging breast) planar images were obtained a few minutes and 4 h after injection. The sentinel node was intraoperatively identified with the aid of patent blue dye and a gamma-ray detection probe. A sentinel node was visualised on the 4-h images in 449 of 501 procedures (90%). This visualisation rate improved from 76% to 94% during the study period. Delayed imaging (5-23 h) in 19 patients whose sentinel nodes failed to show, resulted in visualisation in four of them. A repeat injection of radiocolloid in 11 patients revealed a sentinel node in six. In the end, the visualisation rate was 92%. The sentinel node was surgically retrieved in 24 of the remaining 42 patients with non-visualisation (57%). Sentinel nodes that were visualised were tumour-positive in 38% and non-visualised sentinel nodes were involved in 50% (chi2, P=0.17). In a multivariate regression analysis, scintigraphic non-visualisation was independently associated with increased patient age (P<0.001), decreased tracer dose (P<0.001) and increased number of tumour-positive lymph nodes (P=0.013). The use of a sufficient amount of radioactivity (at least 100 MBq) is recommended for lymphatic mapping in breast cancer, especially in elderly women. Delayed imaging and re-injection of the radioactive tracer increase the visualisation rate. The non-visualised sentinel node can be identified intraoperatively in more than half of the patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1619-7070
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
305-11
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12002703-Adult,
pubmed-meshheading:12002703-Age Factors,
pubmed-meshheading:12002703-Aged,
pubmed-meshheading:12002703-Aged, 80 and over,
pubmed-meshheading:12002703-Breast Neoplasms,
pubmed-meshheading:12002703-Carcinoma,
pubmed-meshheading:12002703-Female,
pubmed-meshheading:12002703-Humans,
pubmed-meshheading:12002703-Lymphatic Metastasis,
pubmed-meshheading:12002703-Middle Aged,
pubmed-meshheading:12002703-Predictive Value of Tests,
pubmed-meshheading:12002703-Preoperative Care,
pubmed-meshheading:12002703-Radiopharmaceuticals,
pubmed-meshheading:12002703-Sensitivity and Specificity,
pubmed-meshheading:12002703-Sentinel Lymph Node Biopsy,
pubmed-meshheading:12002703-Technetium
|
pubmed:year |
2002
|
pubmed:articleTitle |
The hidden sentinel node in breast cancer.
|
pubmed:affiliation |
Department of Surgery, The Netherlands Cancer Institute, Amsterdam. ptanis@nki.nl
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study
|